• Login
    View Item 
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    •   UoN Digital Repository Home
    • Journal Articles
    • Faculty of Health Sciences (FHS)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV-2/HIV-1 Coinfected Persons: A Randomized Controlled Trial.

    Thumbnail
    View/Open
    Abstract.pdf (216.4Kb)
    Date
    2013
    Author
    Mujugira, A
    Magaret, AS
    Celum, C
    Baeten, JM
    Lingappa, JR
    Morrow, RA
    Fife, KH
    Delany-Moretlwe, S
    de Bruyn, G
    Bukusi, EA
    Karita, E
    Kapiga, S
    Corey, L
    Wald, A
    Type
    Article
    Language
    en
    Metadata
    Show full item record

    Abstract
    Background. Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herpes simplex virus type 2 (HSV-2) in HSV-2-serodiscordant heterosexual couples by 48%. Whether suppressive therapy reduces HSV-2 transmission from persons coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) is unknown. Methods. Within a randomized trial of daily acyclovir 400 mg twice daily in African HIV-1 serodiscordant couples, in which the HIV-1-infected partner was HSV-2 seropositive, we identified partnerships in which HIV-1-susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk of HSV-2 transmission. Results. We randomly assigned 911 HSV-2/HIV-1-serodiscordant couples to daily receipt of acyclovir or placebo. We observed 68 HSV-2 seroconversions, 40 and 28 in acyclovir and placebo groups, respectively (HSV-2 incidence, 5.1 cases per 100 person-years; hazard ratio [HR], 1.35 [95% confidence interval, .83-2.20]; P = .22). Among HSV-2-susceptible women, vaginal drying practices (adjusted HR, 44.35; P = .004) and unprotected sex (adjusted HR, 9.91; P = .002) were significant risk factors for HSV-2 acquisition; having more children was protective (adjusted HR, 0.47 per additional child; P = .012). Among HSV-2-susceptible men, only age ≤30 years was associated with increased risk of HSV-2 acquisition (P = .016). Conclusions. Treatment of African HSV-2/HIV-1-infected persons with daily suppressive acyclovir did not decrease risk of HSV-2 transmission to susceptible partners. More-effective prevention strategies to reduce HSV-2 transmission from HIV-1-infected persons are needed.
    URI
    http://www.ncbi.nlm.nih.gov/pubmed/23901094
    http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/57409
    Citation
    J Infect Dis. 2013 Nov;208(9):1366-1374. Epub 2013 Jul 30.
    Publisher
    University of Nairobi
     
    School of Medicine
     
    Collections
    • Faculty of Health Sciences (FHS) [10067]

    Copyright © 2019 
    University of Nairobi Library
    | UoN Quality Policy | Send Feedback
     

    Browse

    All of UoN Digital RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Copyright © 2019 
    University of Nairobi Library
    | UoN Quality Policy | Send Feedback